Second Peoples Hospital of Cixi City

Xushan, China

Second Peoples Hospital of Cixi City

Xushan, China
SEARCH FILTERS
Time filter
Source Type

Weng J.-F.,Second Peoples Hospital of Cixi City | Chen J.,Second Peoples Hospital of Cixi City | Hong W.-C.,Second Peoples Hospital of Cixi City | Luo L.-F.,Second Peoples Hospital of Cixi City | And 2 more authors.
Peptides | Year: 2013

Visfatin is a newly identified pro-inflammatory adipokine and a genetic polymorphism -1535 C > T located in the visfatin gene promoter has been suggested to be associated with the regulation of visfatin expression in some inflammatory illness. However, there were some conflicting results regarding whether this variant is functional or not. This study aimed to examine the relations of the -1535 C > T single nucleotide polymorphism (SNP) of visfatin gene to the plasma visfatin and C-reactive protein concentrations in traumatic brain injury (TBI). 318 Chinese Han patients with TBI were recruited in this study. Plasma visfatin and C-reactive protein levels were significantly different between the genotypes in the SNP-1535 C > T even after adjustment for age, sex and body mass index. The genotype C-C had the highest plasma visfatin and C-reactive protein concentrations. The plasma visfatin and C-reactive protein concentrations between the variant genotypes C-T and T-T did not differ significantly. Plasma visfatin level was significantly associated with plasma C-reactive protein level using multivariate linear regression. Thus, the SNP-1535 C > T of visfatin gene seemed to be potentially involved in the inflammatory component of TBI through a decreased production of visfatin. © 2013 Elsevier Inc. All rights reserved.


Chen J.,Second Peoples Hospital of Cixi City | Weng J.-F.,Second Peoples Hospital of Cixi City | Hong W.-C.,Second Peoples Hospital of Cixi City | Luo L.-F.,Second Peoples Hospital of Cixi City | And 2 more authors.
Peptides | Year: 2012

Higher plasma visfatin concentration has been associated with ischemic stroke. Thus, we sought to investigate change in plasma visfatin level after traumatic brain injury and to evaluate its relation with disease outcome. Seventy-six healthy controls and 98 patients with acute severe traumatic brain injury were recruited. Twenty-seven patients (27.6%) died and 48 patients (49.0%) suffered from unfavorable outcome (Glasgow outcome scale score of 1-3) in 6 months. On admission, plasma visfatin level was increased in patients than in healthy controls and was highly correlated with Glasgow Coma Scale score. A multivariate analysis identified plasma visfatin level as an independent predictor for 6-month mortality and unfavorable outcome. According to receiver operating characteristic curve analysis, the predictive value of the plasma visfatin concentration was similar to Glasgow Coma Scale score's. In a combined logistic-regression model, visfatin did not improve the predictive value of Glasgow Coma Scale score. Thus, increased plasma visfatin level is associated with 6-month clinical outcomes after severe traumatic brain injury. © 2012 Elsevier Inc.

Loading Second Peoples Hospital of Cixi City collaborators
Loading Second Peoples Hospital of Cixi City collaborators